CJC-1295 NO DAC (Mod GRF 1-29) (5MG)

What Is CJC-1295 No DAC and Why Buy It for Research?

Buy CJC-1295 No DAC in Switzerland for research into pulsatile growth hormone release, GHRH receptor signaling, and physiological GH axis dynamics. Specifically, CJC-1295 No DAC (also known as Modified GRF 1-29, Mod GRF 1-29, or GRF(1-29) NH₂) is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH).

Structurally, it features the sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ with a molecular weight of approximately 3,367.9 Da.

CJC-1295 No DAC represents the active peptide component of the CJC-1295 platform without the Drug Affinity Complex (DAC) moiety that enables albumin binding. This distinction is pharmacologically critical: without the DAC, the peptide has a plasma half-life of approximately 30 minutes rather than 6 to 8 days. Furthermore, the peptide incorporates four strategic amino acid substitutions D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27 that confer resistance to dipeptidyl peptidase-IV (DPP-IV) and other plasma proteases.

The D-Ala substitution at position 2 is the most critical modification, as native GHRH is rapidly inactivated by DPP-IV which cleaves the Tyr1-Ala2 peptide bond. Consequently, this single modification extends the biological half-life from less than 7 minutes (native GHRH) to approximately 30 minutes. Moreover, Core Peptides supplies CJC-1295 No DAC as a lyophilized powder in a 5mg format exclusively for laboratory use. Therefore, researchers seeking to source this pulsatile GHRH analog for their work will find it readily available when they buy CJC-1295 No DAC in Switzerland.

CJC-1295 No DAC Research Overview: Buy CJC-1295 No DAC in Switzerland for Pulsatile GHRH Studies

Centrally, research into CJC-1295 No DAC has focused on its function as a short-acting GHRH analog that produces discrete, physiological GH pulses similar to natural GHRH signaling. Endogenously, growth hormone-releasing hormone (GHRH) stimulates the pituitary gland to release growth hormone (GH) in a pulsatile manner, which is essential for normal growth, metabolism, and physiological function. However, the native GHRH peptide has an extremely short half-life of less than 7 minutes due to rapid enzymatic degradation by DPP-IV, limiting its utility as a research tool.

CJC-1295 No DAC overcomes this limitation through four strategic amino acid substitutions that confer resistance to DPP-IV and other plasma proteases, extending the half-life to approximately 30 minutes. Unlike the DAC-conjugated version which produces sustained elevation, the no-DAC variant produces a short, sharp GH pulse lasting approximately 1-2 hours per injection, closely mimicking the natural, pulsatile release of GHRH.

This rapid clearance allows GH to return to baseline between doses, preserving the physiological on/off pattern of GH secretion. Notably, CJC-1295 without DAC and modified GRF 1-29 refer to the same tetra-substituted GHRH (1-29) sequence the stabilised backbone without the albumin-binding DAC group. Accordingly, researchers who buy CJC-1295 No DAC in Switzerland from Core Peptides can support their investigations into pulsatile GHRH signaling, physiological GH dynamics, and synergistic peptide combinations.

How Does CJC-1295 No DAC Work in Research?

Mechanistically, CJC-1295 No DAC operates through GHRH receptor activation with a pulsatile pharmacokinetic profile that closely mimics endogenous signaling.

GHRH Receptor Activation

CJC-1295 No DAC functions as a GHRH analog that binds to and activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs. This binding triggers a downstream signaling cascade via Gs/cAMP/PKA signaling that results in GH synthesis and secretion.

The peptide is derived from the biologically active N-terminal fragment of human GHRH (residues 1-29), which represents the minimum sequence required for full agonist activity at the GHRH receptor. Additionally, the peptide is C-terminally amidated (CONH₂ rather than COOH), consistent with the natural processing of GHRH, contributing to improved metabolic stability by preventing carboxypeptidase degradation.

DPP-IV Resistance

The four strategic amino acid substitutions in CJC-1295 No DAC confer resistance to enzymatic degradation. Specifically, the D-Ala substitution at position 2 introduces a non-natural amino acid configuration that DPP-IV cannot recognize, rendering the peptide resistant to this primary degradation pathway.

Furthermore, the Gln substitution at position 8 (replacing Asn) prevents non-enzymatic deamidation, preserving receptor binding and improving shelf stability. The Ala substitution at position 15 (replacing Gly) enhances metabolic stability by reducing susceptibility to endopeptidases. Moreover, the Leu substitution at position 27 (replacing Met) prevents oxidation of the sulfur atom, providing improved chemical stability.

Pulsatile GH Release Profile

With a half-life of approximately 30 minutes, CJC-1295 No DAC produces discrete 1-2 hour GH pulses per injection that closely mimic endogenous pulsatile GH secretion. GH returns to baseline between doses, preserving the physiological on/off pattern that is essential for normal GH axis function. As a result, this pulsatile profile contrasts with the sustained elevation produced by the DAC-conjugated version.

Why Is CJC-1295 No DAC Studied in Switzerland?

Primarily, researchers study CJC-1295 No DAC because it represents a well-characterized short-acting GHRH analog that enables investigation of pulsatile GH secretion, physiological GHRH signaling, and synergistic peptide combinations. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying physiological GH dynamics, somatotroph function, and growth hormone axis regulation.

Research has demonstrated CJC-1295 No DAC’s relevance across multiple domains. For instance, the no-DAC variant is the typical pairing partner with GHRPs such as Ipamorelin because its 30-minute half-life matches Ipamorelin’s approximately 2-hour half-life, which preserves a pulsatile pattern. Furthermore, studies have suggested that GHRH may support the centers in the nervous system for sleep.

The non-DAC version produces physiological pulsatile GH release with rapid clearance and better safety reversibility, but requires multiple daily injections. The choice between DAC and no-DAC forms depends on the specific research question: for studies requiring sustained elevation of GH to investigate long-term effects, CJC-1295 with DAC is often preferred; for experiments aiming to mimic the natural physiological rhythm of GH secretion, CJC-1295 without DAC is the more appropriate choice.

Additionally, CJC-1295 No DAC has been identified in seized doping material as a modified growth hormone releasing factor that can be used as a performance-enhancing substance in sports. Ultimately, researchers who buy CJC-1295 No DAC in Switzerland gain access to a comprehensive research tool for investigating pulsatile GHRH signaling, physiological GH dynamics, and GHRP synergy.

CJC-1295 No DAC Research Areas in Laboratory Studies

Research Area	Focus	Evidence Level
Pulsatile GH Secretion	Physiological GH patterning, 30-minute half-life, discrete GH pulses	Mechanistic / Preclinical
GHRH Receptor Signaling	GHRH-R activation, Gs/cAMP/PKA signaling, somatotroph function	Mechanistic / In Vitro
DPP-IV Resistance	Tetrasubstituted amino acids, enzymatic stability, peptide design	Mechanistic
GHRP Synergy	Combination with Ipamorelin, GHRP-2, GHRP-6, synergistic GH release	Preclinical
Physiological GH Dynamics	Pulsatile vs. sustained exposure, natural GHRH signaling mimicry	Mechanistic / Preclinical
Sleep and Neurological Research	GHRH effects on sleep centers, nervous system support	Emerging Research

CJC-1295 No DAC Compared With Related Research Compounds

Compound	Research Focus	Mechanism / Target	Key Difference
CJC-1295 No DAC (Mod GRF 1-29)	Pulsatile GH release, physiological GHRH signaling	GHRH-R activation only; 30-minute half-life	29-amino acid; pulsatile release; rapid clearance
CJC-1295 DAC	Sustained GH/IGF-1 elevation, long-acting GHRH signaling	GHRH-R activation + DAC albumin conjugation	30-amino acid; half-life 6-8 days; sustained elevation
Sermorelin	GHRH analog for GH research	GHRH-R activation	Short half-life (~5 min); no DPP-IV resistance
Tesamorelin	GHRH analog for metabolic research	GHRH-R activation	Approved for HIV-associated lipodystrophy; longer half-life

Comparatively, CJC-1295 No DAC differs from other GHRH analogs in its pulsatile pharmacokinetic profile and DPP-IV resistance. On the one hand, CJC-1295 DAC achieves a half-life of approximately 6 to 8 days through covalent albumin binding, providing sustained GH and IGF-1 elevation. On the other hand, CJC-1295 No DAC has a half-life of approximately 30 minutes and produces discrete GH pulses that closely mimic natural GHRH signaling. In contrast, sermorelin has a half-life of approximately 5 minutes and lacks the DPP-IV-resistant modifications that extend CJC-1295 No DAC’s half-life. The no-DAC variant is frequently used in combination with GHRPs such as Ipamorelin because its half-life matches Ipamorelin’s roughly 2-hour half-life, preserving a pulsatile pattern.

Research Applications for CJC-1295 No DAC in Switzerland

Scientists have investigated CJC-1295 No DAC across several research domains:

• Pulsatile GH Secretion Research: Researchers use CJC-1295 No DAC to study physiological GH patterning, discrete GH pulses, and the importance of pulsatile vs. continuous GH exposure.
• GHRH Receptor Signaling: The compound is employed to investigate GHRH-R activation, Gs/cAMP/PKA signaling, and somatotroph function in pituitary research models.
• DPP-IV Resistance and Peptide Design: Studies have examined the tetrasubstituted amino acid modifications and their role in extending peptide half-life.
• GHRP Synergy Studies: CJC-1295 No DAC is used in combination with GHRPs such as Ipamorelin, GHRP-2, and GHRP-6 to investigate synergistic GH release and pulsatile amplification.
• Physiological vs. Sustained GH Dynamics: The compound serves as a tool for comparing pulsatile versus sustained GHRH-analogue exposure in research models.
• Sleep and Neurological Research: Emerging studies have explored GHRH’s effects on sleep centers and nervous system support.

Evidently, researchers who buy CJC-1295 No DAC in Switzerland gain a valuable addition to any laboratory toolkit focused on growth hormone axis signaling, physiological GH dynamics, and GHRP synergy research.

CJC-1295 No DAC Product Specifications

Specification	Details
Product Name	CJC-1295 No DAC (Modified GRF 1-29)
Alternative Names	Mod GRF 1-29, CJC-1295 without DAC, GRF(1-29) NH₂, Modified GRF(1-29)
Amount	5mg
Form	Lyophilized powder
Purity	Not verified
Amino Acid Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
Peptide Length	29 amino acids
Molecular Formula	C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight	3,367.9 Da (free base)
CAS Number	863288-34-0
Half-Life	Approximately 30 minutes
Research Category	Growth Hormone Peptides / Anti-Aging & Longevity
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below, protected from light
Solubility	Soluble in water and bacteriostatic water; reconstitute slowly

How to Evaluate CJC-1295 No DAC Quality for Research

When sourcing CJC-1295 No DAC peptide for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the compound’s molecular weight (3,367.9 Da) and sequence.
• Purity Assessment: High-performance liquid chromatography (HPLC) should verify purity, with ≥98% considered standard for research-grade material.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results including HPLC purity and identity confirmation.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, amount (5mg), sequence, molecular formula, CAS number, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated, dark conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptides and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation, purity percentage as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptide they are using in their laboratory investigations.

Storage and Stability of CJC-1295 No DAC

Core Peptides supplies CJC-1295 No DAC as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Reconstitute only immediately before use with appropriate sterile solvents (e.g., bacteriostatic water)
• Inject solvent slowly against the inner wall of the vial rather than directly onto the powder; do not shake
• Gently roll the vial in a circular motion to dissolve
• Once reconstituted, refrigerate at 2°C to 8°C and utilize within 14-21 days
• Protect from light; do not freeze reconstituted solution

Frequently Asked Questions About Buying CJC-1295 No DAC in Switzerland

What is CJC-1295 No DAC?

Specifically, CJC-1295 No DAC (Modified GRF 1-29, Mod GRF 1-29) is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH) with four DPP-IV-resistant substitutions and no Drug Affinity Complex moiety.

What is CJC-1295 No DAC researched for?

Primarily, researchers study CJC-1295 No DAC for its role in pulsatile GH release, physiological GHRH signaling, and synergistic combinations with GHRPs. Studies have investigated its pharmacokinetic profile, GH pulse dynamics, and growth hormone axis signaling.

How does CJC-1295 No DAC work?

Mechanistically, CJC-1295 No DAC binds to and activates the GHRH receptor on pituitary somatotrophs, triggering GH synthesis and secretion via Gs/cAMP/PKA signaling. The peptide’s half-life of approximately 30 minutes produces discrete GH pulses that closely mimic natural GHRH signaling.

What is the amino acid sequence of CJC-1295 No DAC?

The amino acid sequence is Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂.

What is the molecular weight of CJC-1295 No DAC?

The molecular weight is approximately 3,367.9 Da.

What is the molecular formula of CJC-1295 No DAC?

The molecular formula is C₁₅₂H₂₅₂N₄₄O₄₂.

What is the CAS number of CJC-1295 No DAC?

The CAS number is 863288-34-0.

What is the half-life of CJC-1295 No DAC?

CJC-1295 No DAC has a half-life of approximately 30 minutes. This is extended from less than 7 minutes for native GHRH through four strategic amino acid substitutions.

How does CJC-1295 No DAC differ from CJC-1295 DAC?

CJC-1295 No DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes and produces pulsatile GH release mimicking natural GHRH signaling. CJC-1295 DAC has a half-life of approximately 6-8 days due to albumin-binding DAC technology and produces sustained GH/IGF-1 elevation.

Is CJC-1295 No DAC approved as a medicine?

No. Regulatory authorities have not approved CJC-1295 No DAC as a medicine, pharmaceutical, or therapeutic agent. It is a research tool for laboratory use only.

Is CJC-1295 No DAC intended for human use?

No. CJC-1295 No DAC is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy CJC-1295 No DAC in Switzerland?

You can buy CJC-1295 No DAC in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate CJC-1295 No DAC quality?

Researchers should look for identity confirmation via mass spectrometry, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in CJC-1295 No DAC may also find the following related compounds relevant to their work:

• CJC-1295 DAC — The long-acting version with Drug Affinity Complex, researched for sustained GH/IGF-1 elevation and weekly dosing protocols.
• Ipamorelin — A GHRP commonly paired with CJC-1295 No DAC for synergistic GH release with minimal cortisol elevation.
• GHRP-2 — A GHRP researched for robust GH release and synergistic combinations with GHRH analogs.
• GHRP-6 — A GHRP researched for GH release, appetite stimulation, and synergistic GH amplification.

Explore Growth Hormone Peptides

CJC-1295 No DAC belongs to the Growth Hormone Peptides category of research compounds. Growth Hormone Peptides products are studied for their potential roles in GH axis signaling, metabolic regulation, and growth-related pathways. Generally, researchers who buy CJC-1295 No DAC in Switzerland often pair it with related compounds in this category to explore complementary pathways in GH research and metabolic studies.

Explore Anti-Aging & Longevity

Researchers studying age-related GH decline, metabolic health, and longevity pathways may also find relevant compounds in the Anti-Aging & Longevity category. CJC-1295 No DAC’s effects on pulsatile GH release make it a valuable tool for investigating physiological GH dynamics and age-related GH axis changes.

Further Research

For researchers seeking to deepen their understanding of CJC-1295 No DAC and its research applications, the following areas may warrant further investigation:

• The relationship between CJC-1295 No DAC-mediated pulsatile GH release and specific downstream signaling pathways in different cell types
• Comparative studies between CJC-1295 No DAC and native GHRH in various GH axis and physiological models
• The potential for synergistic GH amplification when combining CJC-1295 No DAC with various GHRPs
• Mechanistic studies on the role of pulsatile versus continuous GH exposure in growth, metabolism, and tissue function
• Exploration of CJC-1295 No DAC’s effects on different tissue systems beyond the GH axis

Research Disclaimer

CJC-1295 No DAC is a research peptide supplied for laboratory research use only. Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.

Finally, all research involving peptides should be conducted by qualified personnel in appropriate laboratory settings with proper safety protocols.